Related Experiment Video
Updated: Jul 26, 2025
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.2K
New Treatment to Prevent Recurring Clostridioides Difficile Infections
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American Journal of Nursing
|June 22, 2023
Summary
The FDA approved Rebyota, a live fecal microbiota treatment, to prevent recurrent Clostridioides difficile infections in adults after antibiotic therapy. This marks a significant advancement in managing difficult-to-treat C. difficile cases.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- Clostridioides difficile infection (CDI) poses a significant health challenge, particularly recurrent cases.
- Antibiotic treatment for recurrent CDI can be limited and may lead to further complications.
- Fecal microbiota transplantation is an emerging strategy for restoring gut microbiota balance.
Purpose of the Study:
- To report the FDA approval of Rebyota, a novel live fecal microbiota product.
- To highlight the indication for Rebyota in preventing recurrent Clostridioides difficile infections in adults.
Main Methods:
- Rebyota is a live microbial product derived from human fecal matter.
- Administration is approved following antibiotic treatment for recurrent CDI episodes.
Main Results:
- FDA approval signifies demonstrated safety and efficacy in clinical trials (details not provided in abstract).
- Rebyota offers a new therapeutic option for adult patients with recurrent C. difficile.
Conclusions:
- The approval of Rebyota represents a milestone in the treatment of recurrent CDI.
- This live fecal microbiota product provides a targeted approach to microbiome restoration and infection prevention.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
218
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
218
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
158
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
158
01:29Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
462
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
462